diethyl oxomalate | 741234-79-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: diethyl oxomalate
• 英文别名: Oxalessigsaeurediethylester；diethyl (E)-2-hydroxybut-2-enedioate
• CAS: 741234-79-7
• 化学式: C₈H₁₂O₅
• 分子量: 188.18
• InChiKey: JILRCVQYCFULEY-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  diethyl oxomalate 在 亚磷酸三苯酯 、 硼氘化钠 、 4 A molecular sieve 、 溴 、 溶剂黄146 作用下， 以 四氯化碳 、 水 为溶剂， 反应 0.17h， 生成 diethyl 2-bromo-2-deuteriobutanedioate
  参考文献：
  名称：

  Behaviour of isomeric methyl ethyl and ethyl methyl halosuccinates under electron impact. Elimination of a halogen atom by a multi-step mechanism

  摘要：

  AbstractThe electron impact mass spectra of isomeric methyl ethyl and ethyl methyl halosuccinates (X = Cl and Br) are surprisingly different. Only the isomers with the ethyl group remote from the halogen give rise to [M ‐ X]+ ions. A low‐energy collision‐induced dissociation study of deuterium‐labelled analogues of the former isomers indicates that the [M ‐ X]+ ions are mixtures of protonated methyl ethyl maleate (major component, > 85%) and fumarate, and the loss of the halogen atom is a multi‐step process including at least two specific hydrogen transfers. Migration of a β‐hydrogen atom to the carbonyl oxygen within the ethoxycarbouyl group produces a primary radical site in a distonic intermediate which, by subsequent abstraction of a hydrogen atom from C(3), triggers the ejection of X from C(2) with concomitant double bond formation. Whereas in the other isomer an [M ‐ X]+ ion is absent or negligible, a characteristic double loss of C2H4 and CO2 is observed.

  DOI：

  10.1002/oms.1210260917
• 作为产物：
  描述：

  sodium (E)-1,4-diethoxy-1,4-dioxobut-2-en-2-olate 在 盐酸 作用下， 以 水 为溶剂， 以83%的产率得到diethyl oxomalate
  参考文献：
  名称：

  Behaviour of isomeric methyl ethyl and ethyl methyl halosuccinates under electron impact. Elimination of a halogen atom by a multi-step mechanism

  摘要：

  AbstractThe electron impact mass spectra of isomeric methyl ethyl and ethyl methyl halosuccinates (X = Cl and Br) are surprisingly different. Only the isomers with the ethyl group remote from the halogen give rise to [M ‐ X]+ ions. A low‐energy collision‐induced dissociation study of deuterium‐labelled analogues of the former isomers indicates that the [M ‐ X]+ ions are mixtures of protonated methyl ethyl maleate (major component, > 85%) and fumarate, and the loss of the halogen atom is a multi‐step process including at least two specific hydrogen transfers. Migration of a β‐hydrogen atom to the carbonyl oxygen within the ethoxycarbouyl group produces a primary radical site in a distonic intermediate which, by subsequent abstraction of a hydrogen atom from C(3), triggers the ejection of X from C(2) with concomitant double bond formation. Whereas in the other isomer an [M ‐ X]+ ion is absent or negligible, a characteristic double loss of C2H4 and CO2 is observed.

  DOI：

  10.1002/oms.1210260917

文献信息

• [EN] SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLES BICYCLIQUES SUBSTITUÉS CONDENSÉS EN 6,5
  申请人：EPIZYME INC

  公开号：WO2014144747A1

  公开（公告）日：2014-09-18

  The present invention relates to azole bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

  本发明涉及唑类双环杂环芳基化合物。本发明还涉及含有这些化合物的药物组合物，以及通过向需要的受试者投与这些化合物和药物组合物来治疗癌症的方法。本发明还涉及利用这些化合物进行研究或其他非治疗目的的用途。
• [EN] PI4KIIIBETA INHIBITORS<br/>[FR] INHIBITEURS DE PI4KIIIBÊTA
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019141694A1

  公开（公告）日：2019-07-25

  The invention relates to compounds of formula (I) which are inhibitors of kinase activity, pharmaceutical formulations containing the compounds and their uses in treating and preventing viral infections and disorders caused or exacerbated by the viral infection wherein R1, R2, R3, R4a, R4b, R4c, R5, W, X, Y and Z are defined herein.

  这项发明涉及式(I)的化合物，这些化合物是激酶活性的抑制剂，包含这些化合物的药物配方以及它们在治疗和预防病毒感染及由病毒感染引起或加重的疾病中的用途，其中R1、R2、R3、R4a、R4b、R4c、R5、W、X、Y和Z在此处定义。
• [EN] SGC STIMULATORS<br/>[FR] STIMULATEURS DE LA SGC
  申请人：IRONWOOD PHARMACEUTICALS INC

  公开号：WO2015089182A1

  公开（公告）日：2015-06-18

  The present patent application discloses at least the compounds according to Formula 1 shown below, or pharmaceutically acceptable salts thereof, wherein ringjB,n, JD, J,0, X, X1, J, RC, and W are as defined herein. These compounds are useful as simulators of soluble sGC.

  本专利申请至少揭示了如下所示的符合Formula 1的化合物，或其药用可接受盐，其中ringjB，n，JD，J，0，X，X1，J，RC和W的定义如本文所述。这些化合物可用作可溶性sGC的模拟物。
• [EN] N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE<br/>[FR] PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES N-SULFONYLÉS ET LEUR PROCÉDÉ D'UTILISATION
  申请人：ABBVIE S Á R L

  公开号：WO2017060874A1

  公开（公告）日：2017-04-13

  The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了一种具有以下结构的化合物（I），其中R1、R2、R3、R4、R5和R6具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个具有结构（I）的化合物组成的药物组合物。
• SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE
  申请人：AbbVie S.à.r.l.

  公开号：US20170101406A1

  公开（公告）日：2017-04-13

  The present invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , and R 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了式（I）的化合物 其中R 1 ，R 2 ，R 3 和R 4 具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个式（I）的化合物组成的药物组合物。